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ABSTRACT 
The oligodendrocyte myelin glycoprotein is a glycosylphosphatidylinositol-anchored protein 
expressed by neurons and oligodendrocytes in the CNS. Attempts have been made to identify 
the functions of the myelin-associated inhibitory proteins (MAIPs) after axonal lesion or in 
neurodegeneration. However, the developmental roles of some of these proteins and their 
receptors remain elusive. Recent studies indicate that NgR1 and the recently discovered 
receptor PirB restrict cortical synaptic plasticity. However, the putative factors that trigger these 
effects are unknown. Since Nogo-A is mostly associated with the endoplasmic reticulum and 
MAG appears late during development, the putative participation of OMgp should be 
considered. Here we examine the pattern of development of OMgp immunoreactive elements 
during mouse telencephalic development. OMgp immunoreactivity in the developing cortex 
follows the establishment of the thalamo-cortical barrel-field. At cellular level, we located OMgp 
neuronal membranes in dendrites and axons as well as in brain synaptosome fractions and 
axon varicosities. Lastly, the analysis of the barrel-field in OMgp-deficient mice revealed that 
although thalamo-cortical connections were formed, their targeting in layer IV was altered and 
numerous axons ectopically invaded layer II-III. Our data support the idea that early-expressed 
MAIPs play an active role during development and point to OMgp participating in thalamo-
cortical connections.  
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INTRODUCTION 
The oligodendrocyte myelin glycoprotein (OMgp) is a glycosylphosphatidylinositol-anchored 
protein expressed by neurons and oligodendrocytes in the central nervous system (CNS) (Habib 
AA et al., 1998; Wang KC et al., 2002). Pioneer genomic studies reported that the omgp gene is 
located within intron 27b of the mouse NF1 gene which encodes to Neurofibromin, a RasGAP 
protein, which, when mutated lead to neurofibromatosis type 1 (NF1) disease (Mikol DD, MJ 
Alexakos et al., 1990). NF1-deficient mice display deficits in cortical development (especially in 
the development of the neocortical barrel-field) (Lush ME et al., 2008). However, although 
function in adult in normal and neural degeneration is revealed, OMgp functions during 
development remain to be established. 
 
OMgp belongs to a group of molecules located in CNS myelin protein fractions, with axon 
outgrowth inhibitory activity (Kottis V et al., 2002; Wang KC et al., 2002). This group also 
includes, Nogo-A (GrandPre T et al., 2000; Huber AB and ME Schwab, 2000; Prinjha R et al., 
2000) and MAG (McKerracher L et al., 1994; Mukhopadhyay G et al., 1994). All three proteins 
may act via the same receptor, the Nogo receptor (NgR1) (Fournier AE et al., 2001; Fujitani M 
et al., 2005) or its paralogues (NgR2 and/or NgR3) or the recently identified PirB (paired 
immunoglobulin-like receptor B) (Atwal JK et al., 2008; Barton WA et al., 2003; Lauren J et al., 
2003; Pignot V et al., 2003; Venkatesh K et al., 2005). The participation and physiology of PirB 
is not fully known. However, NgR1 may form a complex with either p75NGFR (Domeniconi M et 
al., 2002; Hu WH et al., 2002) or TROY (Domeniconi M and MT Filbin, 2005; Shao Z et al., 
2005)  which would transduce intracellular signals by activating RhoA (Domeniconi M and MT 
Filbin, 2005; Shao Z et al., 2005; Yamashita T and M Tohyama, 2003). In addition, NgR1 may 
also interact with another co-receptor, Lingo-1 (Llorens F et al., 2008; Mi S et al., 2004), which 
mediates intracellular signaling through the serine-threonine kinase WNK1 (Zhang Z et al., 
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2009). Subsequent studies pointed out that ligands and their receptors may play crucial roles 
after lesion or in neurodegenerative diseases (e.g., (Fournier AE et al., 2002; Gil V et al., 2006; 
Jokic N et al., 2006; Karnezis T et al., 2004; Park JH et al., 2006; Teng FY and BL Tang, 2005)) 
or following alcohol abuse (Okamoto H et al., 2006). However, while these MAIPs are widely 
expressed in the adult CNS, emerging data indicate that some of them may play additional roles 
at early stages of brain development, since they are expressed before NgR1 and long before 
the onset of brain myelination. A recent example has been reported for Nogo-A with high 
neuronal expression and different roles during neuronal migration, neurite formation or 
oligodendrocyte maturation in the developing telencephalon (Mingorance-Le Meur A et al., 
2007; Pernet V et al., 2008; Zhao XH et al., 2007). Another example is Lingo-1 (a co-receptor of 
NgR1, (Carim-Todd L et al., 2003; Mi S et al., 2004)) which can also bind to the postmitotic 
neuron-specific zinc finger protein Myt1l (Llorens F et al., 2008). In the studies of Habib et al., 
and Vourc'h et al., omgp expression was analyzed during postnatal development but earlier 
developmental stages were not studied.  
 
Although oligodendrocyte expression of OMgp occurs at nodes of Ranvier with distinct roles in 
regulating nodal formation and function during CNS myelination (Apostolski S et al., 1994; 
Huang JK et al., 2005; Nie DY et al., 2006), several studies suggest that OMgp is mainly a 
neuronal protein, with is also expressed in oligodendrocytes (Habib AA et al., 1998; Hunt D, RS 
Coffin et al., 2002; Koyama Y et al., 2008). However, the functions of neuronal OMgp during 
development have not been fully explored. Here we examined the pattern of OMgp expression 
in the embryonic mouse forebrain using a well characterized antibody, paying special attention 
to neurons. In addition, the cellular distribution and expression changes of neuronal OMgp 
protein were analyzed in vivo and in vitro. We report that neuronal OMgp is present at early 
stages of development (from E14), localized in the growing axons during axonal tract formation 
following the maturation of cortical connections (e.g., perforant pathway, thalamo-cortical 
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projection, etc). In addition, subsets of hippocampal interneurons express OMgp in the adult 
stages. At cellular level, OMgp is present in the neuronal membrane, synaptosomal fractions 
and axonal varicosities in primary hippocampal cultures. Lastly, the role of OMgp in the 
organization of thalamo-cortical connections was analyzed in omgp -/- mice. The barrel-field of 
omgp -/- mice was altered and ectopic thalamic axons were seen in layer II-III. Taken together, 
our data provide a detailed characterization of the OMgp protein expression in the embryonic 
mouse telencephalon and indicate that OMgp has a role in axonal target specification and 
synaptic plasticity. 
 7 
MATERIALS AND METHODS 
 
Animals 
All animal experiments were carried out in accordance with the guidelines of the European 
Union (2003/65/CE) and current Spanish regulations (BOE 252/34367-91, 2005) for the use of 
laboratory animals. All experimental protocols were also approved by the local Ethical 
Committee. A total of 30 pregnant OF1 mice (Iffra Credo) were used. The morning of plug 
detection was considered as embryonic day 0 (E0) and the day of birth as postnatal day 0 (P0). 
Animals were killed at the following stages: E14, E16, P0, P5, P7, P10, P15, P21 and adults. 
Six to twelve animals (from two or more different litters) were used for each stage. In addition, 5 
omgp -/- mice (stage P7) from two different litters were also used. omgp -/- mice were 
generated in the laboratory of Binhai Zheng (University of California, San Diego, USA). A 
detailed description of gene targeting at OMgp has recently been published (Lee JK et al., 
2009). Briefly, the second exon, which contains all the coding sequence of the OMgp, is 
deleted, resulting in a null allele. This deletion does not interfere with NF1 expression (see 
below). 
   
Antibodies  
The following primary antibodies were used: OMgp (goat polyclonal, AF1674, R&D Systems, 
MN,1:3000 for IHC, 1:200 for IF and 1:1000 for Western blot), Nogo-A (rabbit polyclonal, 1:200, 
Santa Cruz Biotechnology, Santa Cruz, CA), MBP (mouse monoclonal, 1:500, Chemicon, 
Temecula, CA), neuron-specific β-III Tubulin (mouse monoclonal,1:2000, Sigma, St. Louis, MO), 
Calbindin-28KD (CALB, rabbit polyclonal, 1:5000, Swant, Bellinzona, Switzerland), Calretinin 
(rabbit polyclonal, 1:500, Swant), CCK (rabbit polyclonal, 1:100, CRB, Cleveland, UK), 
Parvalbumin (rabbit polyclonal,1:250, Swant), Somatostatin (SOM, rabbit polyclonal, 1:5000, 
Swant), SNAP-25 (SMI81, mouse monoclonal, 1:5000, Covance, Princeton, NJ), Syntaxin 1 
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(mouse monoclonal, clone HPC-1, 1:5000, Sigma), Synaptophysin (mouse monoclonal, 1:1000, 
Dako, Glostrup, Denmark), Synapsin (rabbit polyclonal, 1:1000, Synaptics System, Goettingen, 
Germany), MAP2 (mouse monoclonal, 1:200, Sigma), Actin (mouse monoclonal, 1:1000, 
Chemicon), serotonin (5-HT) transporter (602-622) (5-HTT, rabbit polyclonal, 1:1000, 
Calbiochem, Gibbstown, NJ), HNK-1(412) (rat monoclonal,1:500, kindly provided by Prof. 
Melitta Schachner), HNK-1 (clone VC1.1, mouse monoclonal, 1:2000, Sigma) and 
Neurofibromin (NF1) (rabbit polyclonal, SC-67, 1:1000, Santa Cruz Biotechnology).  
 
Preparation of adult brain myelin 
CNS myelin was isolated following the procedure described by Norton and Poduslo (Norton WT 
and SE Poduslo, 1973). Briefly, adult Sprague-Dawley rat brains were homogenized in 0.32 M 
sucrose at 4º C in a Dounce homogenizer. This homogenate was layered over 0.85 M sucrose 
solution and centrifuged at 25,000 r.p.m for 30 min. The CNS myelin at the interface of the two 
sucrose layers was collected in water and centrifuged at 25,000 r.p.m for 15 min. The resultant 
pellet was obtained, collected in water and centrifuged at 10,000 r.p.m for 10 min twice. The 
white pellet was then suspended in 0.32 M sucrose and the initial gradient was replicated as 
described previously. Finally the myelin was removed from the interface and washed in water 
and spun at 25,000 r.p.m for 10 min to remove sucrose. The final pellet was freeze-dried 
overnight, and protein content was determined using the BCA protein assay kit (Pierce, 
Rockford, IL). 
 
Cell transfection and OMgp detection 
EBNA-293T cells were cultured with Dulbecco´s modified Eagle´s medium (DMEM), 
supplemented with 10% fetal bovine serum, glutamine, and antibiotics (all purchased from 
GIBCO Life Technologies, Paisley, UK). Cells were grown in 35-mm ø 6-well multiplates (Nunc, 
Roskilde, Denmark) containing 10-mm ø glass coverslips to 60-70% confluence and transfected 
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with pCMV-SPORT6-OMgp (full length cDNA clone IRAVp968C0766D purchased from RZPD 
(Germany)) using Lipofectamine-Plus reagents according to the manufacturer’s instructions 
(GIBCO Life Technologies). Seventy-two hours later, cells were scraped and harvested in 
Laemmli sample buffer. Cell extracts were separated by 8% SDS-PAGE electrophoresis, 
electrotransferred to nitrocellulose membranes and immunoblotted with OMgp antibody. In 
parallel, protein samples of total adult brain and myelin extract were also included in the 
experiment as controls. 
 
Immunohistochemical methods  
For immunohistochemistry, fetuses were removed by caesarean section after deep anesthesia 
of the mother with chloral hydrate (3.5 mg/Kg i.p. injection) and transcardially perfused with 4% 
paraformaldehyde dissolved in phosphate buffered saline (PBS) 0.1 M. Postnatal mice were 
anesthetized with chloral hydrate and perfused. After perfusion, brains were removed and post-
fixed in the same solution for 12 hours, cryoprotected in 30% sucrose and sectioned on a 
freezing microtome (Leica, Wetzlar, Germany) (50 µm thick for E16 and 30 µm for P0-adult). 
They were then processed for the immunocytochemical detection of OMgp following an 
immunoperoxidase protocol. Briefly, free-floating sections from different developmental stages 
were processed in parallel. Free-floating sections were rinsed in 0.1 M PBS and endogenous 
peroxidase activity was blocked by incubation in 3% H2O2 and 10% methanol dissolved in 0.1 M 
PBS. After extensive rinsing, sections were incubated in 0.1 M PBS containing 0.2% gelatin, 
10% normal goat serum, 0.2% glycine and 0.2% Triton-X 100 for 1 hour at room temperature. 
Afterwards, sections were incubated for 36 hours at 4° C with the primary antibody. Thereafter, 
sections were incubated with secondary biotinylated antibodies (2 hours, 1:200 diluted) and 
Streptavidin-Horseradish peroxidase complex (2 hours, 1:400 diluted). Peroxidase activity was 
revealed with 0.025% diaminobenzidine (DAB) and 0.003% hydrogen peroxide. After rinsing, 
sections were mounted onto slides, dehydrated, and coverslipped with EukittTM (Merck, 
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Darmstadt, Germany). In embryonic stages, the peroxidase activity was developed following the 
intensification  method of Hancock (Hancock MB, 1986), using DAB-nickel ammonium sulfate 
as chromogen. Immunocytochemical controls, including omission of the primary antibody or its 
replacement by normal serum, prevented immunostaining.  
 
To characterize OMgp expression in adult hippocampal interneurons, additional sections from 
p21-adult brains were processed for double immunofluorescence detection of OMgp and 
several markers of local circuit neurons such as Calbindin, Parvalbumin, and Calretinin; or 
neuropeptides (CCK and SOM) by using Alexa-Fluor 488 and  Alexa-Fluor 568 tagged 
secondary antibodies (Molecular Probes, Eugene, OR). Sections were mounted on Fluoromount 
(Vector Labs, Burlingame, CA) and analyzed on an Olympus Fluoview SV 500 confocal 
microscope. All images were obtained in sequential scanning laser mode to avoid fluorochrome 
cross-excitation. 
 
To determine differences between omgp -/- and omgp +/+ cortical barrel-fields, coronal sections 
of P7 pups were processed in parallel in blind experiments. After genotype identification by 
Western blotting the parietal cortex was photodocumented using an Olympus BX61 microscope 
equipped with cooled digital DP72L camera. Pictures were densitometricaly analyzed using the 
Image-J software (NIH, USA). Brightness and contrast were calibrated in each picture using a 
pseudo-color lookup table (Rainbow RGB LUT) settled between 108 (background) and 248 
(maximum) gray scale values.  
 
Western blotting techniques 
Mice were anesthetized, their brains were dissected out and the telencephalic portion was 
homogenized on ice in homogenization buffer containing 150 mM NaCl, 1 mM EDTA, 10% 
glycerol, 1% Triton X-100, and 1x protease inhibitor cocktail. The homogenate was clarified by 
 11 
centrifugation at 13,000 g for 15 min, and the protein content of soluble fractions was 
determined using the Bio-Rad detergent-compatible assay. Tissue extracts (30 µg) were boiled 
in Laemmli sample buffer at 100º C for 10 min, followed by 8% SDS-PAGE, and electro-
transferred to nitrocellulose membranes (Amersham Biosciences, England, UK). Following 
transfer, membranes were incubated overnight at 4º C with α-OMgp antibody, α-Nogo-A or α-
MBP and α-Tubulin to ensure equal amounts of protein in all samples. Membranes were 
subsequently incubated with peroxidase-tagged secondary antibodies (α-IgG raised in goat, 
rabbit or mouse respectively, Dako) and peroxidase activity was visualized using the ECL-plus 
kit (Amersham Biosciences). Cell extracts from OMgp transfected EBNA-293T cells were used 
as an internal control. 
 
Primary neuronal cultures and immunocytochemical methods 
E16 mouse brains were dissected in PBS containing 0.6% glucose and the hippocampus was 
dissected out. After gentle trypsinization, tissue pieces were dissociated by gentle sweeping. 
Cells were then counted and seeded onto poly-D-lysine-coated coverslips in Neurobasal 
medium containing B27 supplement (GIBCO Life Technologies). Cells were cultured for 7 days. 
Coverslips were fixed in 2% buffered paraformaldehyde,  permeabilized with Triton X-100 in 
PBS 0.1 M and blocked with 10% normal serum in PBS 0.1 M. Cells were sequentially 
incubated overnight with primary antibodies at 4º C and then with Alexa Fluor-tagged secondary 
antibodies for 2 hours. After rinsing in PBS, cells were stained with Bisbenzimide (Hoescht 
32444, 1 µM in PBS 0.1 M, for 10 min), rinsed, mounted on Fluoromount (Vector Labs) and 
analyzed with a confocal microscope (TCS SPII, Leica). To determine whether hippocampal 
neurons express OMgp, we incubated the cultures with α-OMgp and the neuronal marker α-
MAP2 antibodies. To study the co-localization of OMgp with presynaptic markers, we labeled 
the cultures with α-OMgp and α-Synapsin antibodies. 
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Synaptosome subfractionation 
Adult mouse forebrains were homogenized in  30 ml of Sol. A buffer (320 mM sucrose, 5 mM 
Na-HEPES/HCl, pH 7.4) with ten strokes at 600 r.p.m in a glass-Teflon homogenizer. The 
homogenate was centrifuged (5,000 r.p.m., SS34 rotor, for 5 min at 4º C). The resulting 
postnuclear supernatant was centrifuged twice at 11,000 r.p.m. (SS34, for 12 min at 4º C) and 
the crude synaptosomal fraction was resuspended in 4-8 ml of Sol. A buffer. This sample was 
layered on top of a discontinuous Ficoll gradient of 12% - 9% - 5%. After centrifugation for 35 
min. at 22,500 r.p.m. in an SW28 rotor (Beckman Coulter Inc., Fullerton, CA) the synaptosomes 
were collected at the 5% - 9% and 9% - 12% interphases and resuspended in 15 ml of Sol. B 
buffer (10 mM glucose, 5 mM KCl, 140 mM NaCl, 5 mM NaHCO3, 1 mM MgCl2, 1.2 mM 
Na2HPO4 and 20 mM Hepes/NaOH, pH 7.4). After centrifugation for 12 min at 11,000 r.p.m. the 
pellet was resuspended in 300 µl of Sol. B buffer and 2.7 ml of H2O. This sample was layered 
on top of a discontinuous sucrose gradient (0.4 M, 0.6 M, 0.8 M, 1.0 M, 1.2 M, 1.4 M, 1.6 M, and 
1.8 M). Gradients were centrifuged for 3 hours at 33,000 r.p.m. in an SW41 rotor (Beckman) 
and were collected in 0.5 ml fractions. The purity of the fractions was assessed with membrane 
markers by immunoblotting with α-Syntaxin 1, α-Synaptophysin and α-SNAP-25 antibodies. 
 
RESULTS 
 
Characterization of α-OMgp antibody  
 
In this study we used a commercial α-OMgp antibody from R&D Systems. This antibody was 
produced in goat immunized with mouse OMgp. However, to further characterize the specificity 
of the α-OMgp antibody we transfected EBNA-293T cells with plasmid encoding mouse OMgp. 
Immunoblot analysis using the α-OMgp antibody (Fig.1A) exclusively detected a band of 
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approximately 120-130 kD in mouse brain extracts, myelin extracts (see material and methods 
for details) and lysates of OMgp-transfected EBNA-293T cells. Labeling was absent in mock 
transfected cells. It has been described that OMgp carries the HNK-1 epitope which is also 
present in other proteins such us NCAM or MAG (Mikol DD, JR Gulcher et al., 1990). To further 
corroborate that the OMgp antibody used in the present study does not recognize the HNK-1 
carbohydrate, adult brain extracts were immunobloted using the OMgp antibody and the HNK1 
antibody (clone VC1.1, Sigma) (Fig. 1B). The HNK-1(VC1.1) recognizes the HNK-1 epitope in 
several brain proteins such us NCAM, MAG and some chondroitin sulfate proteoglycans of 
different molecular weight. HNK-1(VC1.1) immunoblots renders a strong smear labeling at > 
180-200 kD and an additional labeling of several bands of less than 150 kD which were not 
recognized by the OMgp antibody (Fig. 1B). In addition, to further corroborate these data in 
tissue sections, coronal brain sections from the same animal were immunostained using the 
HNK-1(412) and OMgp antibodies (Fig. 1C-D). The pattern of staining was completely different. 
Specific areas of the telencephalon (e.g., hippocampal fimbria, the anterior commissure or 
globus pallidus) were HNK-1(412)-positive. In contrast, although cortical layer IV was labeled 
with OMgp, did not show HNK-1(412) labeling (Fig. 1 C-D). Lastly, the OMgp antibody did not 
label any band in omgp -/- derived protein extracts (see below) nor in omgp -/- brain sections 
(not shown). We conclude that the goat α-OMgp used in the present study only recognized 
OMgp.  
 
Developmental expression of OMgp during brain development 
 
To determine the expression levels of OMgp during development, we first performed a Western 
blot analysis of protein extracts from developing telecephalon (Fig. 2). The results were 
compared with the developmental expression of Nogo-A and the Myelin Basic Protein (MBP) in 
parallel immunoblots. Immunoblot analysis using the rabbit α-Nogo-A antibody detected a band 
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of approximately 200-210 kD that decrease from E16 to adult stages (Fig. 2). In parallel 
immunoblots, a pale band of OMgp was first seen at E16. OMgp levels increased from P0 
onwards reaching maximum levels in the adult. Similar postnatal results were reported by 
Vourc'h et al., using semi-quantitative RT-PCR (Vourc'h P et al., 2003). In contrast, MBP, a 
marker of the myelination, was detected only from P10 onwards in brain extracts. In a recent 
study (Mingorance A et al., 2005), we described that the first relevant expression of the MAG, a 
marker of myelinating oligodendrocytes, appeared at P8-P10 in the cortical white matter which 
correlates with MBP expression revealed by immunoblotting. Taken together, our data indicate 
that OMgp is expressed at embryonic stages long before the onset of the brain myelination, 
which suggests that OMgp may play additional roles during perinatal development as reported 
for other MAIPs (e.g., NogoA, (Mingorance-Le Meur A et al., 2007; Mingorance A, E Soriano-
Garcia et al., 2004; Montani L, B Gerrits, P Gehrig, L Dimou et al., 2009)).  
 
Next, we aimed to corroborate these data by analyzing the protein expression pattern of OMgp 
during telencephalic development in brain sections, from E14 until adult stages (Fig. 3). Coronal 
or longitudinal sections from developmental series were immunohistochemicaly processed. The 
antibody mainly labeled neurons, although strong staining was also observed at late postnatal 
stages in white matter tracks, and labeled oligodendrocytes were identified in longitudinal spinal 
cord sections with similar morphologies and localization to those reported in oligodendroglial-
like cells in paranodal sections (Huang JK et al., 2005) (Fig. 3M, see also Fig. 2 of Huang et al., 
for details). 
 
At E14, OMgp immunoreactivity was almost absent from the mouse telencephalon (Fig. 3A) 
except for mammillotegmental and mammillothalamic tracts and raphe dorsalis and dorsal 
thalamus nuclei (data not shown). At E16, OMgp labeling was prominent in the 
pyriform/entorhinal region (Fig. 3B), and after nickel-intensified DAB intensification, projecting 
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neurons in layer II-III were seen over the intense neuropil which expands to layer I and lower 
layers of the pyriform/entorhinal cortex. In addition, pale neuropil staining was seen in the 
stratum lacunosum-moleculare of the developing hippocampus at these stages. At P0, strong 
immunoreactivity was also observed in the amygdaloid complex and several hypothalamic 
nuclei (Fig. 3C-D). At P5, puncta-like immunocytochemical staining was observed in all 
neocortical areas with higher levels in lateral than medial cortical regions. Particularly, pale 
OMgp staining was observed in all cortical layers in contrast to layer IV where, in the parietal 
cortex, immunostaining elements were grouped in clusters corresponding to barrels while septa 
were clearly defined (Fig. 3D, G). In addition, Purkinje cells and axonal tracts of the cerebellum 
were also stained at P5 (not shown). At P8-P10, the barrel-field was clearly identifiable and 
increasing OMgp labeling was observed in subgranular cortical layers in the parietal cortex as 
well as in the formerly less immunoreactive regions of the cortex, striatum and dorsal thalamic 
nuclei (Fig. 3E, H-I). From P15-onwards the labeling of the cortical barrel-field was diluted with 
the intense OMgp immunoreactivity in the telencephalon (Fig. 3F, J). Particularly in the 
hippocampus, at P5 but especially at P8-P10, the stratum lacunosum-moleculare and the 
molecular layer of the dentate gyrus and the stratum oriens displayed strong OMgp 
immunoreactivity (Fig. 3E, K). From P15 to P21, the staining of the stratum lacunosum-
moleculare gradually decreased to an intensity that was similar to that in the stratum radiatum 
but lower than in the stratum oriens. In the cerebellum, as indicated above, Purkinje cells were 
stained from P5 onwards (Fig. 3L). 
 
OMgp expression by adult hippocampal interneurons of the CA1 region 
 
Habib and co-workers reported OMgp in local and projection neurons (Habib AA et al., 1998). In 
addition, in the Allen Brain Atlas, OMgp mRNA is expressed in neurons throughout the CNS. 
These data were also confirmed by Hunt and co-workers (Hunt et al., 2002) and recently by 
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Koyama et al., (Koyama Y et al., 2008). In previous studies we  analyzed the developmental 
expression of myelin associated proteins and receptors in the entorhino-hippocampal system in 
mouse, rat and human (Gil V et al., 2006; Llorens F et al., 2008; Mingorance A, X Fontana et 
al., 2004; Mingorance A et al., 2005). Thus, to analyze the pattern of labeling of OMgp in the 
adult hippocampus, we processed horizontal and coronal sections of the adult hippocampal 
formation (Fig. 4). We found that OMgp was expressed by numerous interneurons mainly in the 
CA1 region (Fig. 4A). OMgp staining in hippocampal neurons delineated the complete neuron 
including dendrite and axon. Cell labeling was intense and several neuronal morphologies, 
ranking from multipolar to bipolar shapes, were observed scattered in plexiform layers (Fig. 4A-
B). Double immunohistochemical labeling of OMgp and markers of local circuit neurons 
illustrated OMgp immunoreactivity in non-pyramidal cells expressing calcium-binding proteins 
(Parvalbumin-, Calretinin- and Calbindin-positive) (see Fig. 4C-E, for examples of double 
labeled Parvalbumin-OMgp interneurons) as well as some neuropeptides (CCK or SOM) (Fig. 
4F-K). Although we were unable to establish a clear and specific co-localization of OMgp with 
particular subsets of hippocampal interneurons, the first appearance of OMgp staining in 
hippocampal interneurons coincided with the first appearance of inhibitory potentials in the 
hippocampus (see discussion). 
 
OMgp co-localizes with presynaptic axonal markers in vitro and with presynaptic 
proteins in synaptosomal fractions in vivo 
 
As indicated, OMgp is present during perinatal development in neocortical layer IV in puncta-like 
staining as well as in developmental axonal tracts. Thus, we next examined the putative 
presence of OMgp at the synapse (Fig. 5). First, OMgp localization was studied in primary 
hippocampal cultures after 7 days in vitro (Fig. 5A-H). In cultured neurons, OMgp completely 
labeled MAP2-positive hippocampal neurons (Fig. 5A-C) but was also present in axonal-like 
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varicosities close to neurites or the perikaryon of other cultured neurons. Further, double 
immunohistochemical studies showed that OMgp co-localized in axonal varicosities with 
presynaptic proteins such as Synapsin (Fig. 5D-H). To further confirm that OMgp was present in 
the presynaptic terminals, we analyzed the distribution of well-known presynaptic markers 
(Syntaxin 1 and SNAP-25) in adult sucrose-fractioned brain synaptosomes and we compared 
their distribution with OMgp by Western blotting. Fractionation of synaptosomal preparation 
showed that OMgp was present in the membrane and vesicular fractions (F11-F17), sharing 
distribution with synaptic markers but not with the cytosolic or mitochondrial fractions (F3-F9, 
F19) (Fig. 5I). Taken together, the data suggest that OMgp is localized in axons and 
synaptosomes in developing and adult neurons. 
 
Altered thalamo-cortical targeting and barrel-field development in omgp -/- mice 
 
As indicated, OMgp is present in developing axonal tracts. To further determine the role of 
OMgp in the development of the cortical barrel-field, we analyzed the distribution of 5-HTT 
immunoreactivity in coronal brain sections from 5 omgp -/- and 6 wild-type mice at P7 (Fig. 6). 
The experiments were conducted blind, with no knowledge of the genotype of the brain being 
processed and all free-floating sections were bulk processed during the immunolabeling. After 
the experiment and data acquisition, the genotype of each mouse was determined by 
immunoblotting (Fig. 6A). First, as indicated, the omgp gene is located within intron 27b of the 
mouse NF1 gene, which encodes to Neurofibromin (Mikol DD, MJ Alexakos et al., 1990). NF1-
deficient mice display deficits in development of the somatosensory barrel-field (Lush ME et al., 
2008). Thus, we aimed to determine whether the pattern of NF1 expression is altered in omgp -
/- mice compared to wild-type mice at the postnatal stages of barrel-field formation. After 
immunostaining, omgp -/- and wild-type mice showed similar patterns of immunostaining in the 
neocortex (Fig. 6B-C) and hippocampus (Suppl. Fig. 1). In addition, cortical layering was 
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maintained in adult omgp -/- mice compared to wild-type (Suppl. Fig. 2). Next, we determined 
that the thalamo-cortical connection is formed in omgp -/- mice. However, our results revealed 
that the distribution of the 5-HTT immunostaining in the barrel-field showed clear differences in 
omgp -/- compared to controls in neocortex. In omgp -/- mice, barrels were less defined in the 
first parietal cortex with numerous 5-HTT positive axons invading ectopically layer II-III (Fig. 6E). 
All the processed mutant mice showed these alterations. In Figure 6 we show the densitometric 
analysis in one of the analyzed mice and its parallel control littermate (Fig. 6F-G). In conclusion, 
omgp -/- mice showed altered distribution of thalamo-cortical axons in cortical layer IV, which 
indicates that OMgp is required to restrict correct thalamo-cortical axon targeting in the 
developing cortical barrel-field. 
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DISCUSSION 
 
Neuronal OMgp expression during telencephalic development. 
 
To date most studies have analyzed the pattern of OMgp expression during postnatal 
development (Habib AA et al., 1998; Vourc'h P et al., 2003) or in adult stages (Funahashi S et 
al., 2008; Hunt D, MR Mason et al., 2002; Lee JK et al., 2009). Some studies reported that 
OMgp is expressed by oligodendrocytes (Funahashi S et al., 2008), while others indicate a 
neuronal expression (Habib AA et al., 1998; Hunt D, RS Coffin et al., 2002; Koyama Y et al., 
2008; Lee JK et al., 2009). These discrepancies in OMgp expression are very similar to those 
observed few years ago with the oligodendroglial and neuronal Nogo-A expression (see 
(Mingorance A, X Fontana et al., 2004) for details).	  From a technical point of view, most authors 
used OMgp immunostaining since mRNA localization in oligodendrocytes is difficult and tissue 
treatments may underestimate the amount of mRNA in neurons (M. Schwab, personal 
communication, see also (Huber AB et al., 2002) for details). However, the available evidence 
indicates that OMgp is a neuronal protein which is also expressed by oligodendrocytes in 
healthy (Hunt D, RS Coffin et al., 2002) or damaged CNS (Guo Q et al., 2007), as well as in 
cultured oligodendrocytes (Habib AA et al., 1998). Interestingly, OMgp was found in the nodes 
of Ranvier, a non-myelinated axon region (Apostolski S et al., 1994; Huang JK et al., 2005; Nie 
DY et al., 2006). Huang et al., reported that OMgp was not localized in compact myelin, but in 
oligodendroglial-like cells, whose processes converge to form a ring that completely encircles 
the nodes (Huang JK et al., 2005).  
 
Our results indicate that the goat α-OMgp antibody recognized endogenous and recombinant 
OMgp protein specifically. OMgp is present along non-myelinated axonal tracts during 
telencephalic development and expressed in cultured MAP2-positive hippocampal neurons and 
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adult hippocampal interneurons in vivo. Taken together, our results reinforce the notion that 
OMgp is expressed in neurons and oligodendrocytes. However, we did not observe OMgp-
positive oligodendrocytes in the telencephalic regions due to the relevant neuropil staining of the 
sections from the second postnatal week onwards. However, in transversal sections of spinal 
cord a similar staining to those presented by Huang and coworkers was observed. 
 
Early expression of OMgp during cortical development. A role in axon target 
specification? 
 
We have determined that OMgp expression begins early in embryonic development long before 
the onset of brain myelination. This suggests that OMgp has additional roles other than the 
formation of the myelin sheath (Nie DY et al., 2006) or preventing axon regrowth after injury (Ji 
B et al., 2008). OMgp immunostaining in developing neocortex follows the targeting of the 
thalamo-cortical projection in the layer IV in mice (Rebsam A et al., 2002, 2005; Rice FL and H 
Van der Loos, 1977). As described, the early cortical barrel in mice appears as a patch around 
P4 and septa become noticeable at P6 (Rice FL and H Van der Loos, 1977). Intrinsic cortical 
connections in the developing somatosensory barrel-field are detected from the first postnatal 
week after barrel formation (P8-P10) coinciding with the first appearance of spontaneous 
inhibitory potentials in middle cortical layers (Luhmann HJ and DA Prince, 1991).  In our study, 
OMgp labeling in layer IV appeared during the first stage of barrel development (P4-P5).This 
suggests that OMgp plays an early role on the fine tuning of the thalamo-cortical axons in the 
developing cortex. This was corroborated by analyzing the parietal barrel-field in omgp -/- mice, 
which displays ectopic 5-HTT labeling in layer II-III. A disrupted barrel-field pattern was also 
reported in nf1 -/- mice (Lush ME et al., 2008) as well in trkb -/- mice or MAOA-trkB double 
knockout (Vitalis T et al., 2002). The omgp -/- mice used in the present study showed a normal 
pattern of NF1 protein compared to wild-type mice. Thus it is unlikely that NF1 is involved in 
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producing the present results. However, the phenotypes of the NF1-deficient mice and the 
OMgp knockout are different. As indicated by Lush and co-workers, NF1 knockout mice showed 
profound differences in cortical layer IV since patterning of cortical cells into barrels was strongly 
reduced compared to wild-type mice (Lush ME et al., 2008). In contrast, the OMgp-deficient 
mice showed no apparent differences in the barrel formation and cortical layering (see Supl. Fig 
2). The deficits observed in the NF1-deficient mice in the thalamo-cortical connection are 
stronger than those observed in the omgp -/- mice. Due to the particular location of the OMgp 
gene into the NF1 locus (see above) we cannot rule out an additional effect of the OMgp 
absence in the NF1 phenotype. However, OMgp expression was not determined in NF1 mice 
(Prof. Luis Parada, personal communication). 
 
On the other hand, it has recently been reported that BDNF, the high-affinity ligand of trkB 
receptor, which plays key roles during cortical development (see e.g., (Alcantara S et al., 
2006)), stimulates the phosphorylation of NgR1 by Casein kinase II, suppressing Nogo-
dependent inhibition of neurite outgrowth in neuroblastoma-derived neural cells (Takei Y, 2009). 
Thus, the absence of TrkB may have a direct effect on NgR1-mediated axon inhibition and 
plasticity. It is no clear, whether OMgp expression is modulated by BDNF through TrkB 
receptor. 
 
OMgp is located at the neuronal membrane (Habib AA et al., 1998) and carries the HNK-1 
epitope (Mikol et al., 1990), which is also present in well-characterized neural adhesion 
molecules such as NCAM, L1 or Tenascin R (see (Vourc'h and Andres, 2004), (Yamamoto S et 
al., 2002) or  (Schachner M et al., 1995) for review). Although our OMgp antibody does not 
recognized HNK-1, it has been reported that similar CA1 adult hippocampal interneurons 
labeled with OMgp are HNK-1-positive. The HNK-1 epitope is involved in synaptic plasticity and 
neuronal physiology both during development and in adulthood (Schachner M et al., 1995; 
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Yamamoto S et al., 2002). Thus, a putative function of OMgp in neuronal physiology cannot be 
ruled out. On the other hand, a putative role of OMgp as an adhesion molecule during axonal 
development cannot be also discarded out either, even if we take into account the modifications 
of the distribution of 5-HTT axons in the omgp -/- mice. Furthemore, the absence of other 
neuronal MAIPs during development in vitro leads to increased neurite length and growth cone 
motility (Mingorance-Le Meur A et al., 2007; Montani L, B Gerrits, P Gehrig, L Dimou et al., 
2009). Although not considered in the present study, we cannot discard a putative function of 
OMgp modulating cytoskeleton dynamics and neurite length. 
 
To our knowledge, this is the first description of a putative function of MAIPs in barrel-field 
formation, and together with other studies (Martin I et al., 2009) the first step towards 
understanding the role of OMgp during cortical development. Although Nogo-A has been 
associated with neurite extension (Mingorance-Le Meur A et al., 2007; Montani L, B Gerrits, P 
Gehrig, L Dimou et al., 2009) its putative role in the development of the somatosensory barrel-
field is unlikely, since cortical layering develops normally in Nogo mutant mice (McGee et al., 
2005; Mingorance-Le Meur et al., 2007). In addition, Nogo-A expression levels do not change 
during the critical period, at least in the mouse visual cortex (P20-P26) (McGee AW et al., 2005) 
and other MAIPs, such as MAG, appear in the white matter of the somatosensory cortex at P5 
(Mingorance A et al., 2005).	   Indeed, numerous studies indicate that non-myelin related 
mechanisms may limit somatosensory barrel-field plasticity because the relevant critical period 
ends earlier in development (P1 to P4), before cortical myelination matures (McGee AW et al., 
2005).	   Thalamo-cortical axon targeting involves the participation of multiple lamina-specific 
molecules but relevantly its fine tuning via neural activity (see (Yamamoto N et al., 2007) for 
review). Thalamic axons grow and reach the cortex in the absence of OMgp and in the absence 
of other MAIPs. Moreover, myelination is absent during early barrel-field formation as indicated 
above, but a role of OMgp via NgR1 (expressed in layer IV neurons at these stages 
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(Mingorance A, X Fontana et al., 2004)) or other receptors (see below) could take place. NgR1 
has recently been implicated in activity-dependent synaptic strength (Lee H et al., 2008). In 
addition, NgR1-mediated signaling from myelin-derived proteins consolidates the neural circuitry 
established during experience-dependent plasticity (McGee AW et al., 2005). Furthermore, a 
recent study described a new MAIPs receptor: PirB (Atwal JK et al., 2008; Filbin MT, 2008) 
which has been implicated in restricting cortical plasticity in the visual cortex (Syken J et al., 
2006). In this scenario, we cannot rule out the participation of OMgp together with others factors 
in restricting cortical plasticity.  
 
Does OMgp play a role at the synapse? 
 
As indicated, emerging descriptions indicate several roles for myelin protein ligands and 
receptors in functions very different from those reported above (for examples see (Mingorance-
Le Meur et al., 2007), (Pernet V et al., 2008), (Montani L, B Gerrits, P Gehrig, A Kempf et al., 
2009) or (Wang YZ et al., 2006)).  Nogo-A has been located at the neuronal synapse at the 
ultrastructural level in the postsynaptic active zone (Liu YY et al., 2003) as well as in developing 
axonal tracts (Mingorance-Le Meur A et al., 2007; Tozaki H et al., 2002). Here we 
demonstrated, using biochemical and immunocytochemical methods, that OMgp is located in 
axonal tracts as well as in synaptosomal fractions and in axonal varicosities. Taken together, 
these data open up the field for a putative role of OMgp at the synapse. Whether these 
functions are structural or associated to neurotransmission warrants further study. 
Unfortunately, our antibody does not react with OMgp in post-embedding protocols so we 
cannot clearly define its location at the synaptic contact, as reported for Nogo-A (Liu YY et al., 
2003). However, its location in puncta-like structures or synaptosomal fractions, points to 
putative neuronal roles at the synapse, which would increase the new unexpected OMgp 
functions. For example, recent studies reported new functions for OMgp in controlling stem cell 
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physiology (Martin I et al., 2009). Whether NgR1 or the recently discovered MAIPs receptor PirB 
or other unknown receptors mediate or participate in these new functions, including the 
targeting of thalamo-cortical axons, needs to be determined. In this respect, Lee and co-workers 
indicates that NgR1 modulates synaptic transmission by regulating FGF2-FGFR-mediated 
signaling (Lee H et al., 2008). It would be of interest to study whether OMgp-NgR1 or PirB 
interactions regulate FGF2 roles in the developing telencephalon. In addition, several HNK-1-
binding molecules located in perineural nets have been described, such as laminin, selectins, 
brevican or aggrecan which also contribute to corticogenesis (Domowicz MS et al., 2003; Hall H 
et al., 1993; Miura R et al., 2001; Needham LK and RL Schnaar, 1993). Interestingly, one of the 
most relevant compounds of the perineural nets is aggregan, which also showed profound 
alterations in expression and distributions after sensory deprivation (McRae PA et al., 2007). 
Further studies will help to answer these challenging questions.    
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FIGURE LEGENDS 
 
Figure 1 
Characterization of α-OMgp antibody. 
A: Immunoblot of OMgp using the goat α-OMgp antibody in adult brain protein extracts, purified 
myelin and protein extracts of OMgp-transfected and Mock-transfected cells. For SDS-PAGE 
and Western blotting, 40 µg of adult and cell protein extracts and 15 and 30 µg of myelin extract 
were used. 
B: Immunoblot in adult brain protein extracts using the goat α-OMgp antibody and the HNK-
1(VC1.1). Blots with HNK-1 showed a pattern of staining (asterisks) different from those seen in 
parallel OMgp blots.  
C-D: Low-power photomicrographs illustrating HNK-1 (C) and parallel OMgp-staining (C). 
Notice the different pattern of staining. Scale bar in C = 500 µm also pertains to D. 
Abbreviations: Fr, Frontal cortex; RS, Retrosplenial cortex; CA1-CA3 cornus ammonis 1-3; DG, 
dentate gyrus; F, Fimbria; Par1-2, Parietal cortex 1 and 2; CPu, Caudate putamen; GP, Globus 
palidus; Th, Thalamus; IC, Internal capsule; AC, anterior commissure; Hy, Hypothalamus; Pir, 
Pyriform cortex; Gu, Gustatory cortex. 
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Figure 2 
 
Developmental expression of Nogo-A, OMgp and MBP in Western Blotting. α-OMgp 
antibody detected a band in brain samples with an apparent molecular weight of 120-130 kD. 
Membranes were reprobed with α-Tubulin antibody for protein standardization. Notice that 
Nogo-A expression started at E16 and continued until adult stages. A faint OMgp band can be 
seen at E16 long before the onset of myelination as marked by the first appearance of MBP 
labeling at P10. 
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Figure 3 
 
Pattern of OMgp protein expression during telencephalic development.   
A-F: General views of mouse brains at different stages during development: embryonic stage 
14 (E14), E16, P0, P5, P10 and P21.  
G-J: High magnifications of the primary somatosensory cortex of mice aged from P5 to P21. 
Notice the relevant staining of the barrel-field at layer IV between P5 and P10. A high 
magnification of an OMgp immunopositive barrel at P7 is shown in the insert. 
K: High-power photomicrograph illustrating OMgp staining in P10 hippocampus.   
L: OMgp staining in the cerebellum at P21. Purkinje cells are strongly labeled. 
M: Transversal section of adult spinal cord labeled with anti-OMgp. An oligodendrocyte-like cell 
is OMgp-positive (arrow) as well as other longitudinal thin processes. 
Abbreviations as in Figure 1 including: AC, amygdaloid complex; HL, hindlimb; H, hippocampus; 
NC, neocortex and I-VIb, cortical layers; gl, granular cell layer; h, hilus; ml, molecular layer; slm, 
stratum lacunosum-moleculare; so, stratum oriens; sp, stratum pyramidale; sr, stratum 
radiatum; GL, granular layer; ML, molecular layer; PCL, Purkinje cell layer; WM, white matter. 
Scale bars: A-F, 500 µm; G-K, 200 µm; L, 100 µm and M, 10 µm. 
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Figure 4 
 
OMgp expression in the adult hippocampus  
A: Low-power photomicrograph of OMgp labeling in the hippocampus.   
B: High magnification of the boxed area in A, OMgp-positive cells in the CA1 region 
corresponded to hippocampal local circuit neurons.  
C-H: Confocal microphotographs illustrating double-labeled (PARV/OMgp) interneurons in the 
stratum oriens (arrows in C-E); (CCK/OMgp) interneurons in the stratum radiatum (arrows in F-
H). Note that some CCK-positive cells are not labeled with OMgp antibody (open arrow in F, H). 
I-K: Confocal microphotographs illustrating double-labeled (SOM/OMgp) interneurons in the 
stratum radiatum (arrows in I-K). Abbreviations as in Figure 3. Scale bars: A, 200 µm; B, 100 
µm and C-K, 25 µm.  
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Figure 5 
 
OMgp expression in cultured MAP2-positive hippocampal neurons and Synapsin-labeled 
presynaptic terminals in vitro.  
A-C: Confocal microphotographs illustrating hippocampal cultures (7DIV) incubated with 
antibodies α-OMgp and α-MAP2 to demonstrate the expression of OMgp in MAP2-positive 
neurons (arrows).  
D-F: Parallel cultures were incubated with antibodies α-OMgp and α-Synapsin to demonstrate 
the presence of OMgp in axon terminals close to neuronal perikaryons (Synapsin-positive, 
arrows).  
G-H: OMgp expression in Sinapsin-positive (arrows) axonal varicosities in cultured hippocampal 
neurons. Note that few OMgp-positive varicosities (arrowheads) are Synapsin negative.  
I: OMgp expression in adult forebrain fractionated synaptosomes. Note that OMgp is detected in 
the same fractions (membrane/vesicles) which are immunoreactive for Syntaxin 1 and SNAP-
25. Scale bars: (A,D,G) 25 µm pertains to (B, E); (C,F) and H, respectively. 
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Figure 6 
 
OMgp immunostaining in the primary somatosensory cortex in omgp -/- mice.  
A: Western blot corroboration of the presence of the OMgp protein in omgp -/- mice and wild-
type controls. 
B -C: Low-power photomicrographs illustrating representative sections of the parietal cortex of a 
wild-type (B) and omgp -/- (C) mouse, immunostained using the α-NF1 antibody.  
D-G: Low-power photomicrographs illustrating representative sections of the somatosensory 
barrel-field in control (D,F) and omgp -/- (E,G) mice. Barrels in mutant mice (arrows in E) 
appeared less defined than in controls and numerous 5-HTT positive axons were seen 
ectopically in layer II-III (arrowheads). After application of the pseudocolor correlation the 
disorganization of the terminal thalamo-cortical field in the somatosensory cortex is better 
demonstrated. In the right, the LUT pseudocolour scale (Rainbow RGB) from the Image-J 
program indicating the grey scale value is shown. Abbreviations as in Figure 3. Scale bars: B 
and D, 100 µm pertains to C and E respectively. F-G, 100 µm. 
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